December 22, 2025 at 04:27PM Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication

Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/K19BazV